Skip to main content
Clinical Trials/ISRCTN45944555
ISRCTN45944555
Active, not recruiting
Phase 3

Evaluation of point of care digital molecular diagnostic tool in malaria chemoprevention in pregnant women in the context of parasite resistance to sulphadoxine-pyrimethamine in a malaria high transmission area of Nchelenge in Zambia

Tropical Diseases Research Centre0 sites254 target enrollmentApril 11, 2024

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Malaria diagnostic and prevention in pregnant women
Sponsor
Tropical Diseases Research Centre
Enrollment
254
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 11, 2024
End Date
July 31, 2025
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Tropical Diseases Research Centre

Eligibility Criteria

Inclusion Criteria

  • 1\. Gestational age of 16 to 26 weeks at enrolment
  • 2\. Asymptomatic\* on presentation
  • 3\. Hb \= 7 g/dL
  • 4\. HIV negative at enrolment
  • 5\. No history of IPTp\-SP or antimalarial drug use during the current pregnancy
  • 6\. At least 15 years old
  • 7\. Residence within the health facility catchment area
  • 8\. Willing to deliver at the health facility
  • 9\. Willing to adhere to the study requirements (HIV voluntary counseling and testing (VCT included)
  • 10\. Ability to provide written informed consent; if the woman is a minor of age/not emancipated, the consent must be given by a parent or legal guardian according to national law

Exclusion Criteria

  • 1\. HIV positive or unknown at enrolment
  • 2\. Hb\<7 g/dl
  • 3\. History of allergic reactions to the study drugs
  • 4\. History of known pregnancy complications or bad obstetric history including pre\-existing illness likely to cause complication of pregnancy such as repeated abortions, stillbirths or eclampsia
  • 5\. History or presence of major illnesses likely to influence pregnancy outcome including hypertension, diabetes mellitus, asthma, epilepsy, renal disease, liver disease, fistula repair, heart disease, or active tuberculosis
  • 6\. Current cotrimoxazole prophylaxis or ARV treatment
  • 7\. Any significant illness at the time of screening that requires hospitalization, including severe malaria
  • 8\. Intent to move out of the study catchment area before delivery or deliver at relative’s home out of the catchment area
  • 9\. Prior enrolment in the study or concurrent enrolment in another study
  • 10\. Unable to take oral medication

Outcomes

Primary Outcomes

Not specified

Similar Trials